2023 World Conference on Lung Cancer (Posters)-EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT)

EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT) - PDF(Slides)

Back to course

Pdf Summary

The study, titled "IMMUNOPREDICT: Predictive toxicity and response to immunotherapy in patients with metastatic non-small cell lung cancer," aimed to determine if the presence of pre-existing autoimmune antibodies (autoAc) or those that arise during immunotherapy treatment are associated with the development of secondary autoimmune effects (irAEs). The study included 31 patients with a median follow-up time of 11.2 months. The overall survival (OS) rate at 6 months was 87% and at 13 months was 70.9%. The progression-free survival (PFS) rate at 6 months was 48.4%. The main objective of the study was to find predictive factors for response and toxicity in immunotherapy treatment.<br /><br />The study found no statistical correlation between the presence of autoAc and the development of irAEs. The research determined that predicting toxicity and response to immunotherapy in patients with metastatic non-small cell lung cancer is complex and requires considering multiple factors. The study analyzed parameters such as the presence of autoAc, complement depletion, lymphocyte immunophenotyping, lymphocyte count, and the patient's general condition.<br /><br />The study did not find significant differences in OS or PFS based on the presence or absence of autoAc or the occurrence of irAEs. There was also no significant difference in OS or PFS between patients with lymphopenia and those without. The study did not find an association between the general condition of the patient and the occurrence of irAEs.<br /><br />The research concluded that there is no simple specific marker to determine which patients will respond or develop toxicities during immunotherapy treatment. Future studies should consider a multidimensional approach to identify predictive factors for response and toxicity in immunotherapy treatment.<br /><br />The study provided insights into the mechanism of action of anti-PDL1 and anti-PD1 drugs, which inhibit the signal transduction between PDL1 and PD1, leading to tumor cell apoptosis.<br /><br />Overall, the study highlighted the complexity of predicting toxicity and response to immunotherapy in patients with metastatic non-small cell lung cancer and emphasized the need for further research to identify reliable predictive factors.

Asset Subtitle

Jessica Nguyen

Meta Tag

Speaker Jessica Nguyen

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

IMMUNOPREDICT

predictive toxicity

response to immunotherapy

metastatic non-small cell lung cancer

autoimmune antibodies

secondary autoimmune effects

overall survival rate

progression-free survival rate

predictive factors

anti-PDL1 drugs